论文部分内容阅读
支气管哮喘是由多种炎性细胞参与的呼吸道慢性炎性疾病,发病机制较为复杂,Th1/Th2比例失衡在支气管哮喘的发病中起着重要作用。寡脱氧核苷酸(CpG-ODN)作为非特异性免疫调节剂,可以使Th1表达上调,从而纠正Th1/Th2比例失衡。CpG-ODN不仅能够有效地抑制过敏性哮喘呼吸道炎症的发展,而且能够逆转这种已建立的炎症,因此,CpG-ODN可能成为治疗过敏性哮喘的一种新手段。
Bronchial asthma is a chronic inflammatory disease of the respiratory tract involved in a variety of inflammatory cells. The pathogenesis is complicated. The imbalance of Th1 / Th2 plays an important role in the pathogenesis of bronchial asthma. As an unspecific immunomodulator, CpG-ODN can up-regulate Th1 expression and thus correct the imbalance of Th1 / Th2 ratio. CpG-ODN can not only effectively inhibit the development of allergic asthma respiratory inflammation, but also reverse this established inflammation, therefore, CpG-ODN may become a new means of treatment of allergic asthma.